Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a ...

An expert said weight loss drugs might help people see faster results, which can give them encouragement to continue. But he ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

After the injection, do not rub the area ... In a comparative clinical trial between Maunza and Wegovy conducted over 72 ...

But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

Q3 2025 Earnings Call Transcript October 29, 2025 Vanda Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is ...

Drug giants Novo Nordisk and Pfizer are locked in a fierce $9 billion bidding war for obesity drug developer Metsera. Novo's ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...